VRTX stock forecast, quote, news & analysis
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases... Show more
Why Vertex Pharmaceuticals (VRTX) Is Down -4.8% in the Last 30 Days
Key Takeaways
- VRTX stock declined -4.8% over the last 30 days amid broader biotech sector weakness and post-earnings profit-taking.
- Over the past quarter, shares fell -1.1%, reflecting moderate volatility after peaking near 52-week highs.
- Recent Q4 earnings beat revenue expectations but missed EPS, contributing to sentiment caution despite raised 2026 guidance.
- Positive clinical data from the RAINIER Phase 3 trial for povetacicept supported long-term optimism, though short-term price pressure persisted.
- Analyst upgrades and price target increases highlight resilient fundamentals in cystic fibrosis franchise and pipeline diversification.
Vertex Pharmaceuticals (VRTX) Company Overview and Market Position
Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company focused on developing transformative medicines for serious diseases. Its core business revolves around small-molecule therapies, with the cystic fibrosis (CF) franchise—led by Trikafta and Kaftrio—generating the majority of revenue. Vertex holds a dominant position in the CF market, treating over 90% of known genetic mutations, which provides stable cash flows and funds pipeline expansion into pain, kidney diseases, and gene editing.
The company's strong fundamentals, including high gross margins above 85% and a robust balance sheet, underpin its resilience. Recent diversification efforts, such as Journavx for acute pain and povetacicept for IgA nephropathy, reduce reliance on CF and position Vertex competitively against peers like REGN and AMGN in biotech. This exposure explains recent stock behavior, balancing growth prospects against sector headwinds like valuation concerns.
Vertex Pharmaceuticals (VRTX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, VRTX stock declined -4.8%, moving from approximately $476.90 to $454.08. The movement was volatile and trend-driven downward, with a peak near $497 before recent dips amid market selling pressure. Volume spiked on down days, indicating profit-taking after earlier gains.
For the past quarter, shares fell -1.1%, from around $459.21 to $454.08. Performance was range-bound between $450 and $510, with steady pressure from broader market trends outweighing company-specific positives. The low beta of 0.31 limited downside relative to the S&P 500, but biotech sector rotation amplified the modest decline.
What Drove VRTX Stock Price in the Last 30 Days
The -4.8% drop in VRTX stock over the past 30 days stemmed primarily from post-earnings reactions and sector sentiment shifts. Q4 2025 results, reported mid-February, showed revenue of $3.19 billion (+9.5% YoY), beating estimates by 1.1%, but adjusted EPS of $5.03 missed consensus by 2.3%. Investors focused on the EPS shortfall and sequential CF sales softening, triggering sales despite raised full-year 2026 guidance to $12.95-13.1 billion.
Biotech sector weakness exacerbated the decline, with the Medical sector down over 5% in the period amid rising rates and risk-off sentiment. However, positive catalysts like March 9's RAINIER Phase 3 interim data—povetacicept achieving 49.8% proteinuria reduction vs. placebo—provided brief support. Analyst actions were mixed but net positive, with upgrades from Maxim Group and price target hikes from Truist and Morgan Stanley to around $550-575, tempering the fall.
What Drove VRTX Stock Performance Over the Last Quarter
The slight -1.1% quarterly decline reflected a tug-of-war between pipeline momentum and macroeconomic pressures. Vertex's CF dominance drove steady revenue growth, but shares pulled back from 52-week highs near $514 amid broader biotech underperformance, influenced by inflation concerns and interest rate hikes impacting growth stocks.
Key narratives included Q4 earnings momentum and RAINIER trial success, signaling expansion into nephrology. Institutional buying remained strong at over 90% ownership, while competition in pain therapies added caution. Cumulative sector rotation away from high-valuation biotechs, combined with profit-taking after YTD gains, exerted the strongest downward pressure, though low volatility preserved relative stability.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI-driven trading bots from hundreds available, which analyze and trade thousands of tickers across various markets. These curated bots highlight those with the strongest recent returns, risk-adjusted performance, and relevance to current market trends. Strategies range from momentum and mean reversion to sector-specific approaches, with varying timeframes like day trading, swing, or long-term holds. Metrics such as win rate, profit factor, and drawdown provide transparency for users. Explore Trending AI Robots to discover tools that adapt to real-time data and potentially enhance your trading edge.
VRTX Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor upcoming Q1 2026 earnings for CF franchise updates and Journavx adoption in pain management. Progress on povetacicept's IgAN filing and full RAINIER data could catalyze sentiment. Industry trends like gene therapy advancements and kidney disease competition warrant attention. Macro factors, including interest rates and healthcare policy shifts, may influence biotech valuations. Strategic developments such as partnerships or regulatory milestones, alongside risks from pipeline setbacks, remain key to watch.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
VRTX sees its Stochastic Oscillator ascending out of oversold territory
On April 09, 2026, the Stochastic Oscillator for VRTX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 54 instances where the indicator left the oversold zone. In of the 54 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on April 13, 2026. You may want to consider a long position or call options on VRTX as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for VRTX just turned positive on April 14, 2026. Looking at past instances where VRTX's MACD turned positive, the stock continued to rise in of 61 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VRTX advanced for three days, in of 353 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
VRTX moved below its 50-day moving average on March 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for VRTX crossed bearishly below the 50-day moving average on March 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for VRTX entered a downward trend on April 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. VRTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.053) is normal, around the industry mean (26.452). P/E Ratio (29.000) is within average values for comparable stocks, (46.078). Projected Growth (PEG Ratio) (2.169) is also within normal values, averaging (1.789). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (9.551) is also within normal values, averaging (320.063).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company that discovers and develops novel, small molecule pharmaceuticals
Industry Biotechnology